[ad_1]
DUBLIN, Oct. 24, 2022 /PRNewswire/ — The “GCC Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The GCC generic injectables market size reached US$ 525.8 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,199.7 Million by 2027, exhibiting a CAGR of 14.74% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic injectables are equivalents of brand-name injectables with respect to quality, dosage, route of administration, performance, strength and intended use. They are used for treating a wide array of life-threatening and chronic diseases including diabetes, cancer, cardiovascular diseases, rheumatoid arthritis, respiratory diseases and osteoporosis.
A rise in the prevalence of various lifestyle diseases in the GCC region has catalyzed the demand for these injectables. The lower cost of these drugs as compared to their branded equivalents further helps in providing substantial savings for the patients and healthcare providers.
Market Drivers:
An increase in the emigrant population along with a rise in the cases of both acute and chronic diseases has challenged the capability of the existing healthcare resources in the region. The resulting surge in the overall healthcare costs has boosted the demand for these injectables. Moreover, upcoming patent expiry of a number of blockbuster drugs prescribed in key therapeutic areas is expected to help in expanding the …
Full story available on Benzinga.com
[ad_2]
Source link
